Epcoritamab Trial Misses Key Survival Endpoint

Genmab A/S and AbbVie Inc. have disclosed a critical clinical outcome for their T-cell engaging bispecific antibody, epcoritamab. The Phase 3 EPCORE DLBCL-1 study, evaluating epcoritamab as a monotherapy for transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma, did not meet its primary endpoint in the United States. The trial's primary endpoint was overall survival, and it failed to show a statistically significant improvement.

Although epcoritamab maintains its accelerated FDA approval, the missed survival endpoint necessitates a comprehensive review of the full data set with regulatory authorities to determine the future course for the drug. Both companies are collaborating with regulators to navigate this situation.

Financially, the companies present contrasting scales but demonstrate robust performance. Genmab reported $2.051 billion in H1 2026 revenue, a 25% increase year-over-year, driven by strong royalty revenues. AbbVie posted $16.99 billion in Q2 2026 net revenues, a 10.2% increase, bolstered by its immunology and neuroscience portfolios. Both companies have also seen positive analyst ratings and pipeline advancements.